Inhibition of methylthioadenosine phosphorylase protects from experimental acute kidney injury.

Methylthioadenosine phosphorylase (MTAP) is a key enzyme in purine metabolism that may influence cellular responses to injury. We evaluated the effects of prophylactic MTAP inhibition in mouse models of ischemia-reperfusion and cisplatin-induced acute kidney injury (AKI). MTAP inhibition was confirmed by the accumulation of methylthioadenosine. Treated mice showed reduced renal injury and decreased tubular damage. Transcriptomic analysis revealed protection from inflammatory and stress pathways while maintaining oxidative phosphorylation, fatty acid metabolism, and epithelial integrity-related genes. Analysis of human single-cell RNA sequencing data from the Kidney Precision Medicine Project indicated that MTAP is highly expressed in kidney injury marker-positive adaptive proximal tubule cells, which display both reparative and maladaptive features during AKI. These findings highlight MTAP as a potential therapeutic target for modulating injury responses in AKI.NEW & NOTEWORTHY We show that prophylactic MTAP inhibition protects against experimental AKI in mice. Transcriptomic data indicate that MTAP inhibition suppresses epithelial stress and maladaptive repair-related gene programs. Single-cell analysis of human AKI biopsies supports a role for MTAP in injured proximal tubule subpopulations, identifying it as a potential therapeutic target in AKI.